DELCATH SYSTEMS, INC. — fact timeline

DELCATH SYSTEMS, INC. reported first quarter ended March 31, 2026 results: revenue $25.0 million, net income Net loss of $1.1 million. Guidance raised.

“Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025”

DELCATH SYSTEMS, INC.: Amended and restated bylaws to update stockholder nomination procedures, officer and chairperson election provisions, indemnification rights, and administrative changes (effective 2025-08-12).

“On August 12, 2025, the Board of Directors (the “Board”) of Delcath Systems, Inc. (the “Company”), acting upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s Amended and Restated By-Laws (the “Bylaws”), effective immediately.”

Bridget Martell was appointed as Class III Director at DELCATH SYSTEMS, INC..

“on May 23, 2024, the Company appointed Bridget Martell, M.A. M.D., as a Class III Director on the Company's Board, commencing on May 23, 2024”

Roger Stoll retired as Director at DELCATH SYSTEMS, INC..

“Following the voting on Proposal 1 (as listed below in Item 5.07) at the Annual Meeting on May 23, 2024, Roger Stoll's previously announced retirement from the Board took effect.”

DELCATH SYSTEMS, INC. reported the first quarter ended March 31, 2024 results: revenue $3.1 million.

“Total revenue for the quarter ended March 31, 2024 was $3.1 million compared to $0.6 million for the same period in the prior year from our sales of HEPZATO in the U.S. and CHEMOSAT in Europe.”

DELCATH SYSTEMS, INC. amended Fifth Amendment with Synerx Pharma, LLC and Mylan Teoranta (effective 2024-04-22).

“On April 22, 2024, Delcath Systems, Inc. (“Delcath”) entered into a Fifth Amendment, effective May 1, 2024 (the “Amendment”), to the License, Supply and Contract Manufacturing Agreement with Synerx Pharma, LLC and Mylan Teoranta, dated October 13, 2010 (as subsequently amended, the “Agreement”), for Delcath’s supply of melphalan hydrochloride (the “Product”).”

DELCATH SYSTEMS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $0.5 million and $2.1 million, respectively. Guidance raised.

“to year-end, on March 19, 2024, the company closed a $7.0 million private placement financing. Total revenue for the quarter and year-ended December 31, 2023, was approximately $0.5 million and $2.1 million, respectively, compared to $0.6 million and $2.7 million for the same periods in the prior year, respectively, from our sales of CHEMOSAT in Europe. Research and”

DELCATH SYSTEMS, INC. entered into Securities Purchase Agreement with certain accredited investors valued at sale of 876,627 shares at $3.72/share and 1,008,102 pre-funded warrants at $3.71/warrant, gross proc (effective 2024-03-14).

“On March 14, 2024, Delcath Systems, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 876,627 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $3.72 per share, and (ii) to certain investors, in lieu of shares of Common Stock, 1,008,102 pre-funded warrants (the “Pre-Funded Warrants”) at a price per Pre-Funded Warrant of $3.71 (the “Warrant Shares” and together with the Shares, the “Securities”).”

John Purpura retired as Chief Operating Officer at DELCATH SYSTEMS, INC..

“As previously reported on February 12, 2024, John Purpura notified the Company of his intent to retire as the Company’s Chief Operating Officer”

Martha S. Rook was appointed as Chief Operating Officer at DELCATH SYSTEMS, INC..

“Effective as of March 18, 2024, Delcath Systems, Inc. (the “Company”) appointed Martha S. Rook, Ph.D., as Chief Operating Officer of the Company.”